About Catabasis Pharmaceuticals (NASDAQ:CATB)
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule, which completed Phase II clinical trial for the treatment of duchenne muscular dystrophy (DMD), as well as Phase I clinical trial for the treatment of additional rare diseases. It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) and malfunctioning of CF transmembrane conductance regulator, as well as for the clearance of pathogens, such as P. aeruginosa and B. cenocepacia; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases consisting of Friedreich's ataxia and amyotrophic lateral sclerosis. In addition, the company offers CAT-2000 compounds, which are SMART linker conjugates of nicotinic acid and EPA that are used for the treatment of nonalcoholic steatohepatitis. Catabasis Pharmaceuticals, Inc. has a pre-clinical joint research collaboration agreement with Sarepta Therapeutics, Inc. to explore a combination drug treatment approach for DMD. The company was founded in 2008 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio-1.37
Forward P/E Ratio-1.87
Sales & Book Value
Price / Sales99.86
Price / CashN/A
Book Value$0.51 per share
Price / Book3.37
EPS (Most Recent Fiscal Year)($1.26)
Return on Equity-150.06%
Return on Assets-103.82%
Catabasis Pharmaceuticals (NASDAQ:CATB) Frequently Asked Questions
What is Catabasis Pharmaceuticals' stock symbol?
Catabasis Pharmaceuticals trades on the NASDAQ under the ticker symbol "CATB."
How were Catabasis Pharmaceuticals' earnings last quarter?
Catabasis Pharmaceuticals Inc (NASDAQ:CATB) announced its earnings results on Thursday, March, 15th. The biotechnology company reported ($0.24) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.31) by $0.07. The biotechnology company had revenue of $0.25 million for the quarter, compared to the consensus estimate of $0.25 million. View Catabasis Pharmaceuticals' Earnings History.
When is Catabasis Pharmaceuticals' next earnings date?
What price target have analysts set for CATB?
6 brokers have issued 1 year price targets for Catabasis Pharmaceuticals' stock. Their predictions range from $2.00 to $9.00. On average, they expect Catabasis Pharmaceuticals' share price to reach $5.6667 in the next year. View Analyst Ratings for Catabasis Pharmaceuticals.
Who are some of Catabasis Pharmaceuticals' key competitors?
Some companies that are related to Catabasis Pharmaceuticals include RedHill Biopharma (RDHL), Aileron Therapeutics (ALRN), KalVista Pharmaceuticals (KALV), Alpine Immune Sciences (ALPN), Columbia Laboratories (JNP), Flex Pharma (FLKS), Agile Therapeutics (AGRX), Aralez Pharmaceuticals (ARLZ), Trillium Therapeutics (TRIL), Sunesis Pharmaceuticals (SNSS), Ophthotech (OPHT), KemPharm (KMPH), Galmed Pharmaceuticals (GLMD), BioLineRx (BLRX), Aptevo Therapeutics (APVO), Advaxis (ADXS), OncoSec Medical (ONCS) and Cardiome Pharma (CRME).
Who are Catabasis Pharmaceuticals' key executives?
Catabasis Pharmaceuticals' management team includes the folowing people:
- Ms. Jill C. Milne Ph.D., Co-Founder, CEO, Pres & Director (Age 50)
- Dr. Andrew J. Nichols Ph.D., Chief Scientific Officer (Age 57)
- Dr. Joanne M. Donovan, Chief Medical Officer & Sr. VP of Clinical Devel. (Age 61)
- Dr. Michael Jirousek Ph.D., Co-Founder and Member of Scientific Advisory Board (Age 59)
- Ms. Deirdre A. Cunnane, Chief Legal Officer (Age 53)
When did Catabasis Pharmaceuticals IPO?
(CATB) raised $60 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and Oppenheimer and Wedbush PacGrow were co-managers.
Has Catabasis Pharmaceuticals been receiving favorable news coverage?
Media coverage about CATB stock has trended positive this week, Accern reports. The research group identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Catabasis Pharmaceuticals earned a news sentiment score of 0.36 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 48.19 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are Catabasis Pharmaceuticals' major shareholders?
How do I buy shares of Catabasis Pharmaceuticals?
Shares of CATB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Catabasis Pharmaceuticals' stock price today?
One share of CATB stock can currently be purchased for approximately $1.72.
How big of a company is Catabasis Pharmaceuticals?
Catabasis Pharmaceuticals has a market capitalization of $51.68 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-27,360,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Catabasis Pharmaceuticals employs 36 workers across the globe.
How can I contact Catabasis Pharmaceuticals?
Catabasis Pharmaceuticals' mailing address is One Kendall SquareBldg. 1400E Suite B14202, Cambridge MA, 02139. The biotechnology company can be reached via phone at 617-349-1971 or via email at [email protected]
MarketBeat Community Rating for Catabasis Pharmaceuticals (CATB)MarketBeat's community ratings are surveys of what our community members think about Catabasis Pharmaceuticals and other stocks. Vote "Outperform" if you believe CATB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CATB will underperform the S&P 500 over the long term. You may vote once every thirty days.
Catabasis Pharmaceuticals (NASDAQ:CATB) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Catabasis Pharmaceuticals (NASDAQ CATB) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 40.70%
Institutional Ownership Percentage: 27.94%
Catabasis Pharmaceuticals (NASDAQ CATB) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|6/30/2015||Medimmune Ventures, Inc.||Major Shareholder||Buy||223,439||$12.00||$2,681,268.00|| |
|6/30/2015||Nicholas Galakatos||Director||Buy||376,695||$12.00||$4,520,340.00|| |
Catabasis Pharmaceuticals (NASDAQ CATB) News Headlines
|Alkermes Rallies as FDA Accepts NDA for Depression Drug|
finance.yahoo.com - April 18 at 8:16 AM
|Catabasis Pharmaceuticals to Present Results from the MoveDMD® Trial of Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 70th Annual Meeting|
finance.yahoo.com - April 18 at 8:16 AM
|Alnylam (ALNY) Reports Positive Data for RNAi Candidate|
finance.yahoo.com - April 18 at 8:16 AM
|Catabasis to cut workforce 42% in restructuring move; shares down 6% after hours|
seekingalpha.com - April 17 at 5:54 PM
|Catabasis Pharmaceuticals Aligns Resources to Focus on Lead Program Edasalonexent for the Treatment of Duchenne Muscular Dystrophy|
finance.yahoo.com - April 17 at 5:54 PM
|Here's Why Geron Stock Surged More Than 90% in 6 Months|
www.nasdaq.com - April 15 at 6:36 PM
|Catabasis Pharmaceuticals Inc (CATB) Given Average Rating of "Buy" by Analysts|
www.americanbankingnews.com - April 11 at 8:06 AM
|Zacks: Brokerages Expect Catabasis Pharmaceuticals Inc (CATB) Will Post Earnings of -$0.23 Per Share|
www.americanbankingnews.com - April 9 at 11:16 PM
|Catabasis Pharmaceuticals (CATB) versus Capricor Therapeutics (CAPR) Head to Head Survey|
www.americanbankingnews.com - April 8 at 5:29 AM
|Catabasis Pharmaceuticals Inc (CATB) Expected to Post Earnings of -$0.23 Per Share|
www.americanbankingnews.com - March 23 at 11:14 PM
|Wired News – FDA Permitted a Single Registration Trial Assessing Eiger BioPharma’s Lonafarnib in HDV to Support NDA Filing|
finance.yahoo.com - March 23 at 8:18 AM
|Wedbush Analysts Boost Earnings Estimates for Catabasis Pharmaceuticals Inc (CATB)|
www.americanbankingnews.com - March 22 at 9:24 AM
|FY2022 EPS Estimates for Catabasis Pharmaceuticals Inc (CATB) Cut by Wedbush|
www.americanbankingnews.com - March 21 at 4:40 PM
|Catabasis Pharmaceuticals (CATB) Rating Increased to Buy at Zacks Investment Research|
www.americanbankingnews.com - March 20 at 8:16 PM
|Catabasis Pharmaceuticals (CATB) PT Raised to $6.00 at Wedbush|
www.americanbankingnews.com - March 20 at 11:31 AM
|Catabasis Pharmaceuticals to Present at Oppenheimer's 28 - Business Wire (press release)|
www.businesswire.com - March 20 at 8:27 AM
|Equities Analysts Set Expectations for Catabasis Pharmaceuticals Inc's Q2 2018 Earnings (CATB)|
www.americanbankingnews.com - March 19 at 2:46 AM
|Catabasis Pharmaceuticals Inc (CATB) Receives Consensus Recommendation of "Buy" from Brokerages|
www.americanbankingnews.com - March 17 at 9:18 AM
|Edited Transcript of CATB earnings conference call or presentation 15-Mar-18 8:30pm GMT|
finance.yahoo.com - March 16 at 6:29 PM
|Catabasis Pharmaceuticals (CATB) Announces Quarterly Earnings Results|
www.americanbankingnews.com - March 16 at 9:28 AM
|Catabasis Pharmaceuticals' (CATB) CEO Jill Milne on Q4 2017 ... - Seeking Alpha|
seekingalpha.com - March 16 at 8:19 AM
|Catabasis Pharmaceuticals Inc (CATB) Short Interest Down 58.8% in February|
www.americanbankingnews.com - March 13 at 1:40 AM
|Catella Strengthens UK Presence by Signing a Conditioned Share Purchase Agreement to Acquire Majority Stake in APAM Ltd|
finance.yahoo.com - March 12 at 9:02 AM
|Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Recent Corporate Developments on Thursday, March 15|
finance.yahoo.com - March 8 at 8:23 AM
|Catabasis Pharmaceuticals (CATB) Set to Announce Earnings on Wednesday|
www.americanbankingnews.com - March 7 at 1:32 AM
|Catabasis Has The Potential To Provide Edasalonexent As Treatment For The Entire DMD Population Not Just A ... - Seeking Alpha|
seekingalpha.com - February 22 at 8:21 AM
|Catabasis Pharmaceuticals Inc (CATB) Receives Consensus Rating of "Buy" from Brokerages|
www.americanbankingnews.com - February 20 at 2:54 PM
|It's Time To Invest In Catabasis Pharmaceuticals Following Impressive Phase 2 DMD Data - Seeking Alpha|
seekingalpha.com - February 17 at 8:14 AM
|Research Analysts Issue Forecasts for Catabasis Pharmaceuticals Inc's FY2022 Earnings (CATB)|
www.americanbankingnews.com - February 15 at 4:28 PM
|Catabasis Pharmaceuticals' (CATB) "Outperform" Rating Reiterated at Wedbush|
www.americanbankingnews.com - February 14 at 8:52 PM
|Today’s Research Reports on Trending Tickers: Catabasis Pharmaceuticals and ImmunoCellular Therapeutics|
finance.yahoo.com - February 14 at 9:43 AM
|Why Catabasis Is Tuesday’s Biggest Winner|
www.msn.com - February 13 at 3:43 PM
|ETF Preview: ETFs, Futures Firmer Ahead as Street Mull Mester Comments, Small Business Optimism Index|
www.nasdaq.com - February 13 at 9:50 AM
|Catabasis Pharmaceuticals Reports Edasalonexent Preserved Muscle Function and Substantially Slowed Duchenne Muscular Dystrophy Disease Progression Through More Than One Year of Treatment|
finance.yahoo.com - February 13 at 9:50 AM
|Catabasis Pharmaceuticals (CATB) Stock Rating Lowered by Zacks Investment Research|
www.americanbankingnews.com - January 29 at 9:36 PM
|Catabasis Pharmaceuticals (CATB) Stock Rating Upgraded by Zacks Investment Research|
www.americanbankingnews.com - January 26 at 7:04 PM
|Catabasis Pharmaceuticals Inc (CATB) Receives Average Rating of "Buy" from Analysts|
www.americanbankingnews.com - January 26 at 8:54 AM
|Catabasis Pharmaceuticals (CATB) Downgraded by Zacks Investment Research|
www.americanbankingnews.com - January 18 at 7:42 PM
|Catabasis Pharmaceuticals (CATB) Upgraded to Buy at Zacks Investment Research|
www.americanbankingnews.com - January 17 at 9:14 PM
|Catabasis Pharmaceuticals (CATB) Rating Lowered to Hold at Zacks Investment Research|
www.americanbankingnews.com - January 10 at 7:46 PM
|Catabasis Pharmaceuticals Inc (CATB) Given Consensus Rating of "Buy" by Brokerages|
www.americanbankingnews.com - January 1 at 8:02 AM
|Catabasis Pharmaceuticals (CATB) Rating Reiterated by Wedbush|
www.americanbankingnews.com - December 15 at 8:38 PM
|Catabasis Pharmaceuticals, Inc. (CATB) Receives Average Recommendation of "Buy" from Analysts|
www.americanbankingnews.com - December 7 at 8:00 AM
|Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne ... - GlobeNewswire (press release)|
globenewswire.com - December 6 at 5:01 PM
|Summit, Santhera, Catabasis and Duchenne UK to Host DMD Awareness Day|
finance.yahoo.com - December 6 at 10:02 AM
|Catabasis Pharmaceuticals (CATB) and The Competition Critical Contrast|
www.americanbankingnews.com - November 23 at 5:24 AM
|Annual Piper Jaffray Healthcare Conference - Business Wire (press release)|
www.businesswire.com - November 21 at 5:09 PM
|Catabasis Pharmaceuticals to Present at 29th Annual Piper Jaffray Healthcare Conference|
finance.yahoo.com - November 21 at 5:09 PM
|Catabasis Pharmaceuticals, Inc. (CATB) Stock Rating Upgraded by Citigroup Inc.|
www.americanbankingnews.com - November 20 at 8:52 PM
|Catabasis Pharmaceuticals, Inc. (CATB) Upgraded to "Buy" by Zacks Investment Research|
www.americanbankingnews.com - November 16 at 5:32 PM
Catabasis Pharmaceuticals (NASDAQ:CATB) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Catabasis Pharmaceuticals (NASDAQ:CATB) Income Statement, Balance Sheet and Cash Flow Statement
Catabasis Pharmaceuticals (NASDAQ CATB) Stock Chart for Friday, April, 20, 2018